Clinical trials: Demodex Blepharitis
Meibomian Gland Dysfunction, Blepharitis
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with Demodex lid infestation.
- Conditions
- Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
- Trial name
- Ersa (NCT05454956)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Blepharitis
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
- Trial name
- Saturn-1 (NCT04475432)
- Testing
- TP-03, 0.25%, TP-03 Vehicle
- Where
- 15 sites in United States
- Volunteers
- 421 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Blepharitis
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
The purpose of this study is to compare the safety and efficacy of TP-03, an eyedrop, to its vehicle control for the treatment of blepharitis due to Demodex, a microscopic mite frequently found in human hair follicles.
- Trial name
- Saturn-2 (NCT04784091)
- Testing
- TP-03, TP-03 Vehicle
- Where
- 21 sites in United States
- Volunteers
- 412 people
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Chronic Blepharitis
Demodex Blepharitis Treatment Study
This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis (reducing ocular demodex counts and achieving…
- Trial name
- DBTS (NCT01647217)
- Testing
- Terpinen-4-ol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- BioTissue Holdings, Inc